{
  "abstract": "Colorectal cancer (CRC) remains a major global health burden, and despite advances in systemic therapy, outcomes for metastatic disease remain poor. A central challenge in CRC immuno-oncology is the limited applicability of immune checkpoint blockade (ICB): only a small subset of patients—those with mismatch repair deficiency (dMMR)—derive substantial benefit, leaving the majority of patients with microsatellite stable (MSS) disease without effective immunotherapeutic options.1 2 This unmet need has driven intensive efforts to identify additional biomarkers that can better stratify patients and guide immunotherapy strategies.",
  "authors": [
    {
      "affiliations": [
        "Division of Colorectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan"
      ],
      "name": "Chao-Yang Chen"
    },
    {
      "affiliations": [
        "Department of Biotechnology Medicine, MacKay Memorial Hospital, Taipei, Taiwan"
      ],
      "name": "Oscar Lee"
    }
  ],
  "title": "CXCR4 in colorectal cancer: from prognostic marker to immunotherapy guide?",
  "uid": "b3dda60c-dad2-5bd3-bb30-6740bbf24742"
}